Filing summary
Filing identity and period: The supplied metadata names Vivosim Labs, Inc. and “2018 Q1,” but the filing is for Organovo Holdings, Inc. and the three months ended June 30, 2018 (its fiscal first quarter of 2019). The filing is a Form 10-Q, signed August 9, 2018.
Business context
Organovo is a biotechnology company developing 3D-bioprinted human liver and kidney tissues for therapeutic research and drug profiling. Its lead therapeutic program targets Alpha-1 antitrypsin deficiency (A1AT); the FDA granted orphan drug designation in December 2017, and the company targeted an IND filing in calendar 2020. Its commercial activities include tissue-based services, cell products, collaborations, licenses, and grants.
Financial results and liquidity
| Metric | Three months ended June 30, 2018 | Prior-year period |
|---|---|---|
| Revenue | $0.689 million | $0.990 million |
| Cost of revenues | $0.120 million | $0.301 million |
| Research and development | $3.379 million | $5.033 million |
| Selling, general and administrative | $4.767 million | $5.856 million |
| Operating loss | $7.577 million | $10.200 million |
| Net loss | $7.416 million | $10.102 million |
| Operating cash flow | $(7.022) million | $(10.653) million |
Revenue included $0.546 million from products and services, $0.043 million from collaborations and licenses, and $0.100 million in grant revenue. Basic and diluted net loss per share was $0.07, versus $0.10. Total costs and expenses were $8.266 million. Cost of revenues was about 17% of revenue in the quarter, compared with about 30% in the prior-year quarter; this comparison includes grant revenue in the revenue denominator.
At June 30, cash and cash equivalents were $39.613 million, with another $0.127 million of restricted cash. Current assets were $42.312 million and current liabilities $3.210 million, for working capital of $39.102 million. Total liabilities were $3.736 million; the balance sheet lists no borrowings. Cash, cash equivalents, and restricted cash declined $4.113 million during the quarter. Financing provided $2.907 million, primarily from ATM stock sales. The company reported 113.318 million shares outstanding at quarter-end.
Changes versus the prior-year quarter
- Revenue declined 30%, mainly because of fewer liver-testing service contracts; product and service revenue fell 42%. Grant revenue added $0.100 million, while collaboration and license revenue was broadly unchanged.
- Operating expenses fell: R&D decreased 33% and SG&A decreased 19%. Management attributed much of the decline to restructuring, lower staffing and related personnel costs, and lower lab services and supplies. Average R&D headcount fell from 82 to 51; average SG&A headcount fell from 37 to 24.
- Net loss narrowed by $2.686 million, and cash used in operations improved by $3.631 million. Management attributed the operating cash-flow improvement to lower adjusted cash losses and a smaller working-capital outflow.
- The company adopted Topic 606 revenue recognition and the restricted-cash cash-flow standard on April 1, 2018. It reported no material financial-statement impact from adopting Topic 606.
Outlook, risks, and notable items
Management stated that available cash and its current operating plan were expected to fund operations for at least 12 months from the financial-statement issuance date. It also said additional capital would be needed to further develop therapeutic tissues and execute its business plan. No quantified revenue, earnings, or profitability guidance was provided.
Near-term priorities included a pre-IND meeting and IND-enabling work for A1AT, selecting a second rare-disease indication, pursuing NASH profiling agreements, growing cell-product revenue, and continuing scientific publications. The company cautioned that future financing may be unavailable or unfavorable; insufficient funding could force delays, cutbacks, program eliminations, or less favorable technology licensing. Further equity financing would dilute shareholders; debt financing could impose payment obligations and restrictive covenants.
Other items: the company reported no recorded legal-loss accrual and no legal matter assessed as probable or reasonably possible with an estimable loss; it nevertheless noted litigation outcomes are uncertain. A related-party services agreement with Cirius Therapeutics generated $42,000 of quarterly revenue. Subsequent to quarter-end, Organovo raised approximately $0.2 million through ATM sales and shareholders approved an increase in authorized common shares from 150 million to 200 million and an additional 11 million shares for the 2012 equity plan. The company reported effective disclosure controls and no material change in internal control over financial reporting.
Investor verification points
- Confirm the issuer and reporting period: the filing is Organovo Holdings’ quarter ended June 30, 2018, notwithstanding the supplied Vivosim Labs/2018 Q1 metadata.
- Assess whether cash burn, revenue trends, and financing access support the stated minimum 12-month runway; the runway statement is based on management’s current operating plan.
- Track execution and timing of the A1AT IND plan targeted for calendar 2020, along with regulatory and development milestones.
- Monitor revenue concentration and the ability of services, products, collaborations, and grants to offset development spending.
- Account for dilution: ATM issuance, outstanding equity awards, and the post-quarter increase in authorized shares and plan capacity.